(Reuters) - Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.
(Reuters) - Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.
(Reuters Health) - When pet owners need to flee from disasters like hurricanes and fires, they often think first of their animals, but a new study suggests a scarcity of pet-friendly emergency shelters could make older evacuees all the more vulnerable.
(Reuters) - UnitedHealth Group Inc, the largest U.S. health insurer, said earnings will grow 13 to 16 percent in 2018 as medical costs remain low, and that it expects to benefit from new insurance products backed by U.S. President Donald Trump.
(Reuters) - Transenterix Inc's chief executive played down on Tuesday the threat posed by his company's surgical robotic system to market leader Intuitive Surgical Inc, saying he did not expect the two to compete head on.
(Reuters Health) - Nonalcoholic fatty liver disease and its more aggressive form, nonalcoholic steatohepatitis, have become the fastest-growing reasons for liver transplants in young Americans, according to a recent study.
WASHINGTON (Reuters) - President Donald Trump's pick for U.S. drug czar withdrew on Tuesday after it become public that he spearheaded a bill that undercut the government's power to crack down on opioid makers that were flooding the market with the addictive painkillers.
LONDON (Reuters) - An experimental cancer drug discovered by Hutchison China MediTech has demonstrated promising activity in shrinking tumors in lung cancer patients whose disease had worsened following treatment with approved medicines.
WASHINGTON (Reuters) - U.S. President Donald Trump said on Monday he would review a report that his nominee for drug czar championed a law that weakened the government's ability to fight the nation's opioid epidemic, and said he could consider jettisoning the pick.
(Reuters) - A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.
WASHINGTON (Reuters) - U.S. President Donald Trump said on Monday that he would "look into" a report that his nomination for drug czar championed a law weakening the Drug Enforcement Administration's capacity to slow the flow of drugs that have fueled the country's opioid epidemic.